🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — March 19, 2026

Across 20 S&P 500 Technology sector filings dated March 19, 2026, dominant themes include explosive revenue growth in semiconductors (Micron +196% YoY Q2 revenue to $23.9B) contrasted with modest IT services expansion (Accenture +8.3% YoY Q2 revenue) and revenue declines in niche tech (MultiSensor AI -25% YoY, Intuitive Machines -7.9% YoY), highlighting divergent performance amid cost discipline reducing losses portfolio-wide (e.g., Mustang Bio net loss -88% YoY, MultiSensor AI -46% YoY). Margin expansions in high-growth names like Micron (gross margin +499% YoY) offset compressions elsewhere (Planet Labs Q4 gross margin -800bps YoY to 54%), with positive forward guidance from Accenture (FY26 revenue 3-5% LC growth, raised) and Planet Labs (FY27 revenue $415-440M). Capital allocation leans shareholder-friendly via repurchases (Accenture treasury shares cost up to $11B), dividends (Palmer Square supplemental $0.01/share, Community Bancorp $0.25/share), and M&A (Intuitive Machines $800M acquisitions, dMY Squared quantum merger). Space tech shows momentum with contract wins and backlog surges (Planet RPOs +106% YoY to $852M, Intuitive backlog $943M), while neutral proxy filings signal routine governance. Portfolio-level trends point to 6/10 filings with revenue growth averaging +70% YoY in outperformers, but mixed sentiment (5 positive, 5 mixed) underscores selective opportunities in semis and space over softening software/services. Overall, bullish for high-conviction growth names with raised guidance, bearish for revenue decliners despite loss narrowing.

10 high priority 10 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 19, 2026

Across 21 NASDAQ-100 related filings from March 19, 2026, dominant themes include explosive growth in semiconductors (Micron +196% YoY revenue) and AI/space sectors (Intuitive Machines $900M-$1B 2026 guidance), contrasted by revenue declines in sensor/AI holdings (MultiSensor -25% YoY) and persistent losses in metals/biotech (Lifezone net loss -$14.1M). Period-over-period trends show 7/21 companies with revenue growth >10% YoY (avg +150%), margin expansions in top performers (Micron gross margin +499% YoY), and widespread loss narrowing (Mustang Bio -88%, MultiSensor -46%). Balance sheets strengthened via financing (Intuitive Machines cash +181% to $582.6M, MultiSensor +459% to $24.4M), with capital allocation favoring debt reduction (Micron LT debt -32%) and dividends (Community Bancorp $0.25/share). Procedural filings (proxies, mergers) signal governance stability but low materiality. Portfolio-level, tech/AI outliers drive bullish sentiment (avg materiality 7/10), implying overweight in semis/space amid positive guidance and backlogs, while monitoring cash burn in pre-revenue explorers.

12 high priority 9 medium 21 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 19, 2026

Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily smaller caps and blue-chips like UPS, CVS), a mixed sentiment prevails with 12/50 showing positive revenue/EBITDA growth (avg +40% YoY where reported, e.g., SOLV Energy +80% Q4 rev), contrasted by 8 cases of declines (avg -20% YoY rev/ARR) and debt stresses; healthcare/services outperform with 4/6 reporting +20%+ rev growth and margin expansion (e.g., Vericel 74% gross margin, +33% Adj EBITDA). Proxy statements dominate (14/50, mostly neutral, materiality 5/10 avg) signaling annual meeting season with May catalysts, while capital allocation leans defensive via dividends (6 declarations totaling ~$0.40-0.46/share quarterly). M&A activity peaks with 5 pending votes (RYVYL merger 99% in favor but adjourned; Vine Hill SPAC venue change) and deals like Aveanna's $175.5M acquisition. No widespread insider trading signals, but major holders noted in funds (GAMCO 9-10%). Forward guidance bullish for 7 cos (e.g., SOLV $3.72-3.82B 2026 rev +50% implied), building Q2 2026 catalysts; portfolio trend: growth outliers in space/health vs stressed balance sheets elsewhere.

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 19, 2026

Across 50 SEC filings for March 19, 2026, key themes include mixed FY2025 financial results with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales), contrasted by declines in digital health (DarioHealth -17% revenue) and energy (Equinor -2.5% revenues). Airlines showed resilience (Republic Airways +13.7% revenue, +32.9% Adj EBITDA), solar outperformed (SUNation +77% Q4 revenue beat), while mining had production gains but cost pressures (Gold Resource + AuEq oz YoY). Capital allocation remains shareholder-friendly with dividends declared (Modiv, Global Net Lease) and News Corp's $1B buyback program ongoing. SPAC extensions (Pyrophyte, Artius II, Rice Acq) signal prolonged deal hunts amid no combinations; RYVYL merger nears approval with 99% yes votes. Routine ABS 10-K compliance across 20+ filings indicates stable servicing with no material issues. Portfolio trend: 7/15 high-materiality firms beat revenue expectations YoY, but 5 saw cash declines; forward catalysts cluster late March (earnings, votes). Implications: Favor growth sectors like semis/biotech; monitor energy/health stress and merger closes for near-term alpha.

37 high priority 13 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 19, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, logistics, services), proxy season dominates with 20+ DEF 14A/DEFA14A filings for AGMs clustered in April-May 2026, emphasizing board elections, say-on-pay, and auditor ratifications amid neutral sentiment. Financial performance is polarized: standout YoY revenue growth in retail/logistics (Five Below +22.9% to $4.76B, FedEx Q3 +8% to $24B, Firefly Aerospace +163% to $159.9M) and industrials (Cardinal Infrastructure +45% to $456M, York Space +52% to $386M), contrasted by declines (FiscalNote FY25 -21% to $95.4M, Crawford -2.3% to $1.31B) and widening losses (Larimar Q4 $62.5M vs prior $28.8M). Capital allocation trends positive with buybacks (Aflac $3.5B/33M shares, Crawford $10.5M up from $3.9M), dividend hikes (Aflac +5.2% to $0.61 Q1 2026, Crawford +3.6% to $0.29), and debt reductions (Crawford -24.8% to $151M, Wolfspeed refinancing $475.9M higher-cost notes). Forward guidance largely raised/affirmed (FedEx FY26 rev growth to 6-6.5%, Firefly $420-450M, Cardinal 20%+ EBITDA margin), signaling resilience in consumer demand despite margin pressures (e.g., Cardinal gross margin -80bps to 14%). M&A/JV activity bullish (UniFirst-Cintas merger, Horizon $100M JV), with no notable insider transactions but major holders like GAMCO/Saba in funds. Portfolio-level: 8/15 key financial filers show >20% rev growth avg +60%, but 5 report margin compression avg -100bps; actionable now on catalysts like FedEx spin-off.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 19, 2026

Across 45 filings in the USA S&P 500 Healthcare stream, biotech and healthcare firms (e.g., Assembly, SELLAS, Humacyte, Inhibrx) dominate with narrowed net losses (avg -20% YoY across 6 biotechs) amid R&D ramps (+16% avg YoY) and key partnerships like Gilead's $35M HPI license to Assembly, but cash burns persist requiring shelf registrations and offerings. Broader filings reveal mixed revenue trends (+1.6% YoY sales at Signet, -5.5% at RCI Hospitality) with margin expansions in retail (Signet +130 bps op margin) contrasting biotech pressures; capital returns strong via dividend hikes (Signet +20% to $0.35, Occidental +8% quarterly) and buyback expansions (News Corp $1B, Niagen to $20M). Clinical catalysts abound in healthcare (SELLAS REGAL 72/80 events, Humacyte Symvess launch), signaling near-term alpha, while non-healthcare financials show proxy governance focus. Portfolio-level: 12/45 filings with YoY revenue growth (avg +25% in biotechs), but 8/45 with SSS declines (avg -3.5%); sentiment mixed/neutral (70%), with healthcare bullish on trials/partners. Implications: Favor biotechs with milestones and cash runway >2yrs; monitor Nasdaq risks and Q2 catalysts for healthcare outperformance vs broader market weakness.

25 high priority 20 medium 45 total filings
· daily

Global High-Priority Regulatory Events — March 19, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include routine ABS servicing compliance affirmations (20+ filings, all neutral with no material issues), SPAC extensions and merger adjournments signaling prolonged dealflow, accretive M&A in credit funds, positive insolvency resolutions, and stark contrasts in financial performance with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales) versus declines in digital health (DarioHealth -17% revenue). Period-over-period trends show robust revenue acceleration in 7 high-materiality filers averaging +80% YoY (Micron, argenx, Republic Airways), margin expansions flipping losses to profits in 3 cases, but cash burn persists in pre-revenue SPACs and health tech. Critical developments like Mount Logan's $100M+ asset acquisition (30% FRE boost), Rajeswari Infrastructure's insolvency resolution, and Cannabist Co's forbearance extension highlight takeover, bankruptcy, and regulatory risks resolving positively or extending stress. Portfolio-level patterns reveal sector divergence: tech/biotech outperformance amid financing activity (debt, equity offerings), financial pledges/encumbrances signaling liquidity strains in promoters (Embassy 21% shares), and neutral governance updates in proxies. No widespread insider trading patterns, but capital allocation leans toward growth/reinvestment over returns, with scheduled events clustering in Q2 2026 offering catalysts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 19, 2026

Two S-1 IPO registration statements filed on March 19, 2026, highlight an active US IPO pipeline targeting autonomous robotics (Exyn Technologies) and nuclear energy (Eagle Nuclear Energy Corp.), reflecting investor interest in AI-driven autonomy and clean energy transitions amid 2026 market recovery. Exyn demonstrates superior operational metrics with positive sentiment (10/10 materiality), including 35% larger volume capture, 44% reduction in survey time (27 to 15 minutes), 97% faster setup (30 to under 1 minute), and 50% cost savings over 10 years in mining case studies, with thousands of autonomous flights since 2016 at Level 4B SAE autonomy. Eagle Nuclear shows neutral sentiment (9/10 materiality) with no revenue or earnings reported through 2025-12-31, but multiple capital raises via Regulation Crowdfunding (2025-04/05) and Private Placements (2024-2025), alongside uranium properties and heavy related-party involvement. No period-over-period financial trends available across filings, but Exyn's operational outperformance vs traditional methods signals strong pre-IPO momentum; Eagle's SPAC ties and offerings indicate funding access despite lacks. Portfolio-level theme: Early-stage IPOs prioritizing tech innovation over current profitability, with Exyn outperforming on metrics (e.g., 1cm accuracy, 2M data points/sec) relative to Eagle's neutral profile. Market implications include potential sector rotation into autonomy/mining/defense and nuclear revival, warranting watch for pricing catalysts.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — March 19, 2026

Across 50 filings dominated by neutral ABS servicing compliance disclosures (30+ filings, materiality 3-5/10), key financial reporters show mixed FY2025/Q2 FY2026 results with standout revenue accelerations in tech/memory (Micron +196% YoY Q2 rev to $23.9B) and retail (Ollie's +16.6% sales to $2.65B), offset by declines in health services (DarioHealth -17% rev) and hospitality SSS (ONE Group -3.7%). Aggregate trends reveal 12/20 high-materiality firms with revenue growth averaging +35% YoY (led by Rubrik +48%, Tigo Energy +91.7%), but margins mixed with expansions in 6 (e.g., Micron gross to $17.8B) vs compressions in 7 (avg -150bps where noted); net losses narrowed in 8 biotechs/small caps (e.g., Mustang Bio -88% YoY). Cash positions strengthened in 10 firms (avg +40% YoY, e.g., FedEx to $8B), but deteriorated in 7 (e.g., Lithium Americas liabilities +900%). SPACs (Artius II, Rice) standard pre-deal with trust growth but deficits. No widespread insider activity reported; capital allocation leans reinvestment over returns amid growth focus. Implications: Bullish tech/retail momentum, biotech turnaround watch, ABS stability signal.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 19, 2026

Across 50 DEF 14A filings, a dominant theme is robust 2025 performance highlighted in 17 positive/mixed sentiment proxies (e.g., revenue records at Vericel +20% CAGR, Occidental $10.5B OCF, TechnipFMC backlog +15% YoY), contrasting neutral governance-focused disclosures in 33 closed-end funds and REITs; period-over-period trends show YoY improvements in cash flows (e.g., TechnipFMC FCF +113%), dividends (Aflac +5.2%, BorgWarner +55%), and buybacks ($3.5B at Aflac), with rare declines like Aflac net earnings -29.2% YoY and Tronox 60% dividend cut. Capital allocation leans shareholder-friendly with $4.8B returned at Aflac and debt reductions (Occidental -$4B principal), signaling financial health amid economic challenges. Board refreshments are common (e.g., Sabre to 10 members, GEHC down to 8), with high say-on-pay support (Brunswick 97%, Tronox 96% avg last 7 yrs). A May 2026 cluster of 20+ annual meetings forms a catalyst calendar for say-on-pay votes and governance shifts. Portfolio-level, energy/industrials outperform (avg TSR +10-14%) vs flat funds, implying rotation into performers ahead of meetings.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 19, 2026

Across 27 filings on USA Executive & Director Changes from March 19, 2026, the dominant theme is neutral board and executive transitions (20/27 neutral sentiment), with routine director retirements/not standing for reelection (e.g., MediaAlpha, TripAdvisor, Tidewater) citing personal reasons and no disagreements, signaling stability rather than distress. Positive appointments dominate in financial services and healthcare (CVS Health, RGA, Array Technologies), adding audit/financial experts amid growth strategies, while isolated financial declines appear in hospitality (RCI Hospitality revenues -5.5% YoY to $279.4M, Bombshells -29.2% YoY). Period-over-period trends show outliers like Byrna Technologies' revenue surge >500% from $17M in 2020 to $118M in 2025 and RCI's share repurchases reducing shares 14% YoY to 7.71M, but no broad portfolio-level deterioration; net income improvements (RCI +$7.8M YoY) offset revenue softness. Forward-looking elements include 2026 compensation plans tying pay to EBITDA/revenue (MediaAlpha 25% PRSUs, Tigo 75% Adj EBITDA), bonus pools (Mercantile $1.21M target), and multiple 2026 annual meetings as catalysts. Capital allocation leans toward retention bonuses and RSUs over dividends/buybacks, with RCI's $45.4M FCF flat YoY highlighting reinvestment potential. Overall, low materiality (avg 5.6/10) suggests limited immediate volatility, but positive hires signal conviction in fintech/healthcare sectors.

27 high priority 27 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 19, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (34 new), dominant themes include aggressive liquidity raises via high-interest debt ($225M American Vanguard term loan, $3.75M SmartKem notes), equity offerings (SAB Biotherapeutics public offer, Twin Vee $1.7M ATM), and covenant amendments/extensions signaling covenant breaches (Cannabist forbearance to Mar25 2026, VINCE Holding receivables tweaks). Nasdaq/NYSE delisting notices hit AVAX ONE, Skye Bioscience, Getty Images for sub-$1 bids over 30 days, amplifying small-cap distress. No broad YoY revenue declines disclosed, but debt reductions (DevvStream -$5.9M net) and refinancings (Wolfspeed $475.9M lower-cost notes) provide relief outliers; forward-looking catalysts cluster in Q2/Q3 2026 closings (Mount Logan acquisition, Collegium AZSTARYS deal). Portfolio trends: 12+ equity offerings risking dilution (avg ~$50M targeted), 8+ credit amendments (e.g., AES change-of-control for merger), 1 RSA (DISH DBS potential Ch11); mixed sentiment (20 positive, 15 neutral, 10 negative). Implications: elevated bankruptcy risk in biotechs/microcaps, watch Mar25 Cannabist deadline and Nasdaq hearings for forced reverse splits/buyouts.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 19, 2026

Three US-listed companies—AVAX One Technology Ltd. (Nasdaq), Skye Bioscience, Inc. (Nasdaq), and Getty Images Holdings, Inc. (NYSE)—received deficiency notices between March 13-17, 2026, for common stock bid/closing prices below $1.00 for 30 consecutive business/trading days, violating Nasdaq Listing Rules 5550(a)(2)/5450(a)(1) and NYSE Section 802.01C. This represents a uniform 30-day period-over-period price decline trend across all filings, signaling broad weakness in share prices with no YoY/QoQ recovery mentioned. No immediate trading suspensions occurred, but high materiality (9/10) and negative sentiment underscore delisting risks, with AVAX securing a hearing stay, Skye gaining 180 calendar days to September 14, 2026, and Getty a six-month cure period. Forward-looking paths include potential reverse stock splits (explicit for Skye, implied elsewhere) and compliance via 10 consecutive days at or above $1.00, though no assurances provided. Portfolio-level pattern: cross-sector small-cap distress (tech, biotech, media), amplifying volatility and potential OTC transfers. Implications include heightened short interest, dilution risks from splits, and time-sensitive catalysts for investor positioning.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 19, 2026

Across 27 filings in the USA Board Room Changes stream (March 19, 2026), the dominant theme is neutral board and executive transitions, with 15/27 involving resignations or non-re-elections not due to disagreements, signaling routine refreshment rather than distress. Positive appointments dominate in financial services and energy sectors (e.g., CVS Health, RGA, Array Technologies), adding expertise in finance, reinsurance, and renewables amid strategic growth needs. Limited period-over-period data shows mixed financial health: RCI Hospitality revenues declined 5.5% YoY to $279.4M with Adjusted EBITDA down to $52.6M in 4Q25, contrasting Byrna Technologies' revenue surge from $17M (2020) to $118M (2025, +500%). No widespread insider selling or buying noted, but capital allocation highlights include RCI's 14% share reduction via buybacks and executive bonus plans tied to metrics like revenue/EBITDA in Tigo Energy and Mercantile Bank. Forward-looking catalysts cluster around 2026 annual meetings for director replacements and scheduled departures (e.g., Clear Secure GC April 3). Overall, low materiality (avg 5.6/10) suggests stable governance with opportunities in expertise-driven boards, but watch hospitality for ongoing SSS declines (-4.4% 4Q25).

27 high priority 27 total filings
· daily

US Merger & Acquisition SEC Filings — March 19, 2026

The USA M&A & Takeover Activity stream reveals intense SPAC activity across 10/12 filings, with new IPOs (Metals Acquisition Corp II $230M, Praetorian $253M total), over-allotment exercises, and multiple BCA extensions (Pyrophyte 5th amendment to Apr 2027, Blue incentive pool to 8%), signaling prolonged deal hunts amid market appetite for fresh capital. Ashford Hospitality Trust's $56.8M hotel sale drove pro forma revenue decline of 1.5% YoY to $1.15B (YE2024) but improved net loss 17% to $68.5M, reflecting deleveraging. Battalion Oil's all-stock acquisition added 7,090 acres and 30 drilling locations, expanding contiguous holdings 35% to 27,097 acres. No insider trading reported; capital allocation focuses on trust funding (Constellation note to $5.25M) and debt repayment. Period trends show stable/no declines in most SPACs, mixed in hospitality; forward deadlines cluster Q2 2026-Q1 2027, building catalyst calendar. Portfolio-level: 7/12 neutral sentiment, 3 positive IPO/amendments, implying SPAC resilience but extension fatigue risk.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 19, 2026

Across 50 overnight SEC filings, standout revenue accelerations dominate in semiconductors (Micron +196% YoY to $23.9B) and biotech (argenx +90% YoY sales to $4.15B), contrasting with declines in digital health (DarioHealth -17% YoY to $22.4M) and energy (Equinor -2.5% YoY to $43.8B), highlighting sector divergence amid mixed economic signals. Airlines (Republic +13.7% YoY revenue) and solar (SUNation +26% FY to $71.9M, beating guidance) show resilience, while SPACs (Artius II, Rice Acquisition) report trust interest offsetting losses but extended deal timelines signal delays. Capital allocation leans positive with steady dividends (Modiv $0.10/month common, Global Net Lease preferreds) and repurchases (News Corp $1B program), but debt stresses emerge (Cannabist forbearance extension, American Vanguard $225M term loan at SOFR+8.25%). Merger catalysts near (RYVYL 99% votes cast, reconvene 3/25) and routine ABS servicing compliance in 20+ filings indicate stable structured finance. Portfolio trend: 7/15 high-materiality filings show revenue growth >20% YoY averaging +80%, but 4 report cash burn or dilution; implications favor selective longs in semis/biotech pre-open.

37 high priority 13 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 18, 2026

FDA approved four original ANDA generics for small-cap biotech sponsors on March 12-13, 2026, spanning PHYTONADIONE, Citalopram Hydrobromide, Potassium Phosphate Dibasic, and Dextromethorphan Hydrobromide—all under standard review with no special designations or specified indications. This cluster signals routine pipeline progress enabling near-term generic entries but highlights zero innovative upside amid pervasive pricing and competitive pressures. Neutral overall for portfolios; monitor launches for modest revenue contributions without differentiation.

4 total filings
· daily

New Drug Approvals (Original) — March 18, 2026

FDA approved four original ANDAs on March 12-13, 2026, for generics from ORBICULAR (phytonadione), Aurobindo Pharma Ltd (citalopram hydrobromide), CAPLIN (potassium phosphate dibasic), and Hetero Labs Ltd III (dextromethorphan hydrobromide), all under standard review with no special designations and unspecified indications/therapeutic areas. These routine approvals signal neutral portfolio additions for sponsors amid typical generic dynamics. No material bullish/bearish divergences; focus on execution risks in commoditized markets.

4 total filings